Previous close | 13.50 |
Open | 13.50 |
Bid | 11.30 |
Ask | 15.00 |
Strike | 50.00 |
Expiry date | 2021-07-16 |
Day's range | 13.50 - 13.50 |
Contract range | N/A |
Volume | |
Open interest | 54 |
Despite a dip in revenue, VIR showcases robust clinical progress and strategic regulatory engagements, underpinned by a strong cash reserve.
Vir Biotechnology (VIR) delivered earnings and revenue surprises of 51.52% and 250.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
SAN FRANCISCO, May 02, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.